Creative Planning cut its holdings in Davita Inc (NYSE:DVA) by 24.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,981 shares of the company’s stock after selling 2,263 shares during the quarter. Creative Planning’s holdings in Davita were worth $379,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Securian Asset Management Inc increased its stake in Davita by 1.7% in the fourth quarter. Securian Asset Management Inc now owns 12,961 shares of the company’s stock valued at $667,000 after purchasing an additional 216 shares during the period. CSat Investment Advisory L.P. increased its stake in shares of Davita by 61.8% during the fourth quarter. CSat Investment Advisory L.P. now owns 581 shares of the company’s stock worth $30,000 after acquiring an additional 222 shares during the period. Moody National Bank Trust Division increased its stake in shares of Davita by 0.3% during the first quarter. Moody National Bank Trust Division now owns 87,943 shares of the company’s stock worth $4,775,000 after acquiring an additional 248 shares during the period. Country Club Trust Company n.a. increased its stake in shares of Davita by 4.5% during the first quarter. Country Club Trust Company n.a. now owns 5,988 shares of the company’s stock worth $325,000 after acquiring an additional 259 shares during the period. Finally, Contravisory Investment Management Inc. increased its stake in shares of Davita by 8.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 3,932 shares of the company’s stock worth $202,000 after acquiring an additional 298 shares during the period. Institutional investors own 87.84% of the company’s stock.
DVA has been the topic of a number of recent analyst reports. SunTrust Banks reiterated a “hold” rating on shares of Davita in a research note on Wednesday, February 20th. Deutsche Bank dropped their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday. Robert W. Baird dropped their price target on shares of Davita from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Friday, February 15th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research note on Thursday, February 21st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $67.78.
Shares of Davita stock opened at $52.38 on Friday. Davita Inc has a 52-week low of $48.25 and a 52-week high of $79.11. The company has a current ratio of 1.72, a quick ratio of 1.70 and a debt-to-equity ratio of 2.09. The stock has a market cap of $8.61 billion, a PE ratio of 14.67, a PEG ratio of 0.57 and a beta of 1.28.
Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.91 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.04). The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.82 billion. Davita had a return on equity of 14.17% and a net margin of 1.40%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 earnings per share. Equities analysts anticipate that Davita Inc will post 4.42 earnings per share for the current fiscal year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Why do companies pay special dividends?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA). Institutional Ownership by Quarter for Davita (NYSE:DVA) Receive News & Ratings for Davita Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Davita and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Creative Planning Sells 2,263 Shares of Davita Inc (DVA)